{"id":"https://openalex.org/W2074635429","doi":"https://doi.org/10.1097/cad.0b013e32831fb500","title":"Sorafenib tosylate in advanced kidney cancer: past, present and future","display_name":"Sorafenib tosylate in advanced kidney cancer: past, present and future","publication_year":2009,"publication_date":"2009-07-01","ids":{"openalex":"https://openalex.org/W2074635429","doi":"https://doi.org/10.1097/cad.0b013e32831fb500","mag":"2074635429","pmid":"https://pubmed.ncbi.nlm.nih.gov/19436197"},"language":"en","primary_location":{"id":"doi:10.1097/cad.0b013e32831fb500","doi":"https://doi.org/10.1097/cad.0b013e32831fb500","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cad.0b013e32831fb500","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018910230","display_name":"Camillo Porta","orcid":"https://orcid.org/0000-0003-2412-1563","observed_orcids":["https://orcid.org/0000-0003-2412-1563"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Camillo Porta","raw_affiliation_strings":["Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital, Piazzale C Golgi, Pavia, Italy. c.porta@smatteo.pv.it","Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital, Piazzale C Golgi, Pavia, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital, Piazzale C Golgi, Pavia, Italy. c.porta@smatteo.pv.it","institution_ids":[]},{"raw_affiliation_string":"Medical Oncology and Laboratory of Pre-Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital, Piazzale C Golgi, Pavia, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060970119","display_name":"Chiara Paglino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151645","display_name":"Policlinico San Matteo Fondazione","ror":"https://ror.org/05w1q1c88","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210151645","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Chiara Paglino","raw_affiliation_strings":["Medical Oncology","IRCCS Fondazione Policlinico San Matteo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology","institution_ids":[]},{"raw_affiliation_string":"IRCCS Fondazione Policlinico San Matteo","institution_ids":["https://openalex.org/I4210151645"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071233660","display_name":"Ilaria Imarisio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151645","display_name":"Policlinico San Matteo Fondazione","ror":"https://ror.org/05w1q1c88","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210151645","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Ilaria Imarisio","raw_affiliation_strings":["Medical Oncology","IRCCS Fondazione Policlinico San Matteo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology","institution_ids":[]},{"raw_affiliation_string":"IRCCS Fondazione Policlinico San Matteo","institution_ids":["https://openalex.org/I4210151645"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065420021","display_name":"Elisa Ferraris","orcid":"https://orcid.org/0000-0001-7720-726X","observed_orcids":["https://orcid.org/0000-0001-7720-726X"]},"institutions":[{"id":"https://openalex.org/I4210151645","display_name":"Policlinico San Matteo Fondazione","ror":"https://ror.org/05w1q1c88","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210151645","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Elisa Ferraris","raw_affiliation_strings":["Medical Oncology","San Matteo Policlinic, Pavia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology","institution_ids":[]},{"raw_affiliation_string":"San Matteo Policlinic, Pavia","institution_ids":["https://openalex.org/I4210151645"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5018910230"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.7764,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.85810801,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"20","issue":"6","first_page":"409","last_page":"415"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sorafenib-tosylate","display_name":"sorafenib tosylate","score":0.9649999737739563},{"id":"https://openalex.org/keywords/advanced-kidney-cancer","display_name":"advanced kidney cancer","score":0.8180000185966492},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.8809999823570251},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.9419999718666077},{"id":"https://openalex.org/keywords/vegf-receptors","display_name":"VEGF receptors","score":0.9559999704360962},{"id":"https://openalex.org/keywords/pdgf-receptor","display_name":"PDGF receptor","score":1.0},{"id":"https://openalex.org/keywords/raf-kinase","display_name":"Raf kinase","score":0.9409999847412109},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.4869999885559082},{"id":"https://openalex.org/keywords/expanded-access-program","display_name":"expanded access program","score":0.8529999852180481},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5360000133514404},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.875},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6880000233650208},{"id":"https://openalex.org/keywords/cross-resistance","display_name":"cross-resistance","score":0.6349999904632568},{"id":"https://openalex.org/keywords/molecularly-targeted-agents","display_name":"molecularly targeted agents","score":0.7829999923706055}],"concepts":[{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.9795724153518677},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7643252015113831},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.6393024921417236},{"id":"https://openalex.org/C2781068499","wikidata":"https://www.wikidata.org/wiki/Q3242950","display_name":"Kidney cancer","level":3,"score":0.629124641418457},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5883979201316833},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5336601734161377},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4825150668621063},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.46296098828315735},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4400116801261902},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.43944311141967773},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.07118663191795349},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/cad.0b013e32831fb500","doi":"https://doi.org/10.1097/cad.0b013e32831fb500","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cad.0b013e32831fb500","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:19436197","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19436197","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.6100000143051147}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":55,"referenced_works":["https://openalex.org/W1816852","https://openalex.org/W83302227","https://openalex.org/W1491779959","https://openalex.org/W1971837077","https://openalex.org/W1973003011","https://openalex.org/W1988935694","https://openalex.org/W1999966467","https://openalex.org/W2014901203","https://openalex.org/W2018348203","https://openalex.org/W2043517828","https://openalex.org/W2049792735","https://openalex.org/W2058285583","https://openalex.org/W2078449820","https://openalex.org/W2079491773","https://openalex.org/W2096057999","https://openalex.org/W2098806433","https://openalex.org/W2099259685","https://openalex.org/W2100066495","https://openalex.org/W2100669312","https://openalex.org/W2104540972","https://openalex.org/W2116177733","https://openalex.org/W2118677643","https://openalex.org/W2135760554","https://openalex.org/W2137988136","https://openalex.org/W2139213909","https://openalex.org/W2139702830","https://openalex.org/W2140765540","https://openalex.org/W2145537131","https://openalex.org/W2149026055","https://openalex.org/W2149456801","https://openalex.org/W2153867442","https://openalex.org/W2156472878","https://openalex.org/W2166271687","https://openalex.org/W2167290534","https://openalex.org/W2211107270","https://openalex.org/W2225644272","https://openalex.org/W2241239684","https://openalex.org/W2243165145","https://openalex.org/W2253554231","https://openalex.org/W2256356298","https://openalex.org/W2265006692","https://openalex.org/W2277267518","https://openalex.org/W2278754305","https://openalex.org/W2288007295","https://openalex.org/W2301603902","https://openalex.org/W2305352133","https://openalex.org/W2524800756","https://openalex.org/W2539182848","https://openalex.org/W2590482740","https://openalex.org/W2591446369","https://openalex.org/W2782677799","https://openalex.org/W4245134796","https://openalex.org/W4248458610","https://openalex.org/W4248865448","https://openalex.org/W6664787387"],"related_works":["https://openalex.org/W2415520711","https://openalex.org/W3014741021","https://openalex.org/W1998292094","https://openalex.org/W2921681242","https://openalex.org/W2589212837","https://openalex.org/W1858153778","https://openalex.org/W2028525468","https://openalex.org/W2287764619","https://openalex.org/W4214548184","https://openalex.org/W2182653302"],"abstract_inverted_index":{"The":[0,16],"objective":[1],"of":[2,10,21,26,34,87,102,198],"this":[3],"paper":[4],"was":[5,54],"to":[6,42,99,116,153,189],"review":[7],"the":[8,19,22,47,52,61,80,121,195,201],"development":[9],"sorafenib":[11,173,199],"tosylate":[12],"in":[13,120,125,133,146,192,200,204,215],"kidney":[14,105,193],"cancer.":[15],"MedLine":[17],"database,":[18],"Proceedings":[20],"Annual":[23],"American":[24],"Society":[25],"Clinical":[27],"Oncology":[28],"meeting,":[29],"as":[30,32,77,79],"well":[31,78],"those":[33],"other":[35,75,158,180,209,218],"key":[36],"international":[37],"meetings":[38],"were":[39],"extensively":[40],"searched":[41],"identify":[43],"relevant":[44],"publications.":[45],"Furthermore,":[46],"authors'":[48],"direct":[49],"experience":[50],"with":[51,156,179,217],"drug":[53],"taken":[55],"into":[56],"account":[57],"when":[58],"commenting":[59],"on":[60],"results":[62],"retrieved.":[63],"Sorafenib":[64],"is":[65,167],"a":[66,109,134,147],"multikinase":[67],"inhibitor":[68],"that":[69],"targets":[70],"VEGF":[71],"and":[72,92,124,169,213],"PDGF":[73],"receptors,":[74],"kinases,":[76],"serine-threonine":[81],"kinase":[82],"Raf.":[83],"Following":[84],"early":[85],"signs":[86],"activity":[88,128],"from":[89],"phase":[90,112],"I":[91],"II":[93],"studies,":[94],"it":[95,150],"has":[96,129],"been":[97,130,186],"shown":[98],"improve":[100],"survival":[101],"pretreated":[103],"advanced":[104],"cancer":[106],"patients":[107,205],"within":[108],"placebo-controlled,":[110],"randomized,":[111],"III":[113],"trial,":[114],"leading":[115],"its":[117,163],"approval":[118],"both":[119],"United":[122],"States":[123],"Europe.":[126],"Its":[127],"subsequently":[131],"confirmed":[132],"real-world":[135],"population":[136],"by":[137],"two":[138,157],"expanded":[139],"access":[140],"programs":[141],"performed":[142],"globally,":[143],"but":[144],"not":[145],"first-line":[148,202],"setting;":[149],"also":[151],"proved":[152],"be":[154,190],"non-cross-resistant":[155],"molecularly":[159,181,210],"targeted":[160,182,211],"agents.":[161,183],"Finally,":[162],"toxicity":[164],"profile,":[165],"which":[166],"acceptable":[168],"highly":[170],"predictable,":[171],"makes":[172],"appealing":[174],"for":[175],"combination":[176,216],"treatments,":[177],"especially":[178,214],"Despite":[184],"having":[185],"already":[187],"demonstrated":[188],"active":[191],"cancer,":[194],"exact":[196],"role":[197],"setting,":[203],"who":[206],"have":[207],"failed":[208],"agents,":[212,219],"deserves":[220],"further,":[221],"prospective,":[222],"studies.":[223]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-15T10:00:46.086208","created_date":"2025-10-10T00:00:00"}